Drug intelligence / Profile preview

TRTP-50X

Development stage: Preclinical
Lead developer: CellinCells
Modality: Tissue Cells → Other Cell Types → Cell Therapies
Administration: Injectable

Overview

TRTP-50X is an organoid-based muscle regenerative cell therapy being developed by CellinCells. It is derived from the company's Tissue Re-modeling Technology Platform (TRTP) and is designed to promote the regeneration of muscle tissue. The therapy is currently in preclinical development (MoA and CMC stages) for the treatment of sarcopenia and diabetic ulcers. By utilizing organoid technology, TRTP-50X aims to provide a more complex and functional cellular structure for tissue repair compared to traditional single-cell therapies.

Beyond the preview

Go deeper on TRTP-50X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRTP-50X.

Explore the full profile